J Cancer 2018; 9(1):54-63. doi:10.7150/jca.22190 This issue Cite

Research Paper

Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy

Ronald Wihal Oei1,2*, Lulu Ye1,2*, Fangfang Kong1,2, Chengrun Du1,2, Ruiping Zhai1,2, Tingting Xu1,2, Chunying Shen1,2, Xiaoshen Wang1,2, Xiayun He1,2, Lin Kong1,2, Chaosu Hu1,2, Hongmei Ying1,2✉

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P.R China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R China.
*Ronald Wihal Oei and Lu-Lu Ye made equal contribution to this work.

Citation:
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J Cancer 2018; 9(1):54-63. doi:10.7150/jca.22190. https://www.jcancer.org/v09p0054.htm
Other styles

File import instruction

Abstract

Objective: To analyze the prognostic value of pre-treatment serum lactate dehydrogenase (SLDH) level in patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.

Methods: From January 2010 to March 2013, 427 eligible patients were reviewed. Pre-treatment SLDH level was measured within 2 weeks prior to treatment. Receiver operating characteristic (ROC) curve analysis was performed to select the optimal cutoff point. The impact of pre-treatment SLDH on overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were analyzed using Kaplan-Meier method and Cox proportional hazards model. Further propensity score matching was carried out to adjust bias.

Results: The optimal cutoff point of 168.5 IU/L was selected based on ROC curve analysis. Multivariate analysis showed that high pre-treatment SLDH level was an independent prognostic factor for OS (P=0.001), PFS (P=0.004) and DMFS (P=0.001). After propensity score matching was performed, it remained to be significantly associated with poor OS (P=0.009), PFS (P=0.015) and DMFS (P=0.008) in the adjusted model.

Conclusion: High pre-treatment SLDH level predicts poor survival in patients with NPC treated with IMRT-based therapy. As a routinely performed biomarker, pre-treatment SLDH can be utilized in combination with current Tumor-Node-Metastasis staging to predict survival and to plan a personalized treatment in these patients.

Keywords: Lactate dehydrogenase, Nasopharyngeal carcinoma, Intensity-modulated radiotherapy, Survival.


Citation styles

APA
Oei, R.W., Ye, L., Kong, F., Du, C., Zhai, R., Xu, T., Shen, C., Wang, X., He, X., Kong, L., Hu, C., Ying, H. (2018). Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. Journal of Cancer, 9(1), 54-63. https://doi.org/10.7150/jca.22190.

ACS
Oei, R.W.; Ye, L.; Kong, F.; Du, C.; Zhai, R.; Xu, T.; Shen, C.; Wang, X.; He, X.; Kong, L.; Hu, C.; Ying, H. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J. Cancer 2018, 9 (1), 54-63. DOI: 10.7150/jca.22190.

NLM
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J Cancer 2018; 9(1):54-63. doi:10.7150/jca.22190. https://www.jcancer.org/v09p0054.htm

CSE
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. 2018. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J Cancer. 9(1):54-63.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.